Northwest Biotherapeutics
NWBO
NWBO was delisted on the 16th of December, 2016.
79 hedge funds and large institutions have $211M invested in Northwest Biotherapeutics in 2015 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 14 closing their positions.
169% more capital inflows, than outflows
Capital inflows: $64.6M | Capital outflows: $24M
45% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.02% less ownership
Funds ownership: 37.53% → 36.51% (-1%)
5% less funds holding
Funds holding: 83 → 79 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
51% less call options, than puts
Call options by funds: $6.46M | Put options by funds: $13.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodford Investment Management
London,
United Kingdom
|
+$35M |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
+$17.2M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.28M |
| 4 |
BlackRock Institutional Trust
San Francisco,
California
|
+$2.05M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$13.6M |
| 2 |
CIBC World Markets
New York
|
-$4.47M |
| 3 |
Whitebox Advisors
Minneapolis,
Minnesota
|
-$1.36M |
| 4 |
Wolverine Asset Management
Chicago,
Illinois
|
-$725K |
| 5 |
Bedell Frazier Investment Counselling
Walnut Creek,
California
|
-$630K |
NWBO Hedge Fund Activity: Q3 2015 in Review
79 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q3 2015, worth a combined $211M — down 28% from $291M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NWBO and 10 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 32 added.
The largest buyer was Woodford Investment Management, adding an estimated $35M. The largest seller was Goldman Sachs, cutting an estimated $13.6M.
- 79 institutional investors held Northwest Biotherapeutics (NWBO) as of Q3 2015, down from 83 in Q2 2015.
- Funds reported $211M of Northwest Biotherapeutics stock for Q3 2015, down 28% quarter-over-quarter.
- 10 funds opened new Northwest Biotherapeutics positions in Q3 2015 and 14 closed out, a net change of -4 holders.
- The largest Northwest Biotherapeutics buyer in Q3 2015 was Woodford Investment Management, an estimated $35M added.
- The largest Northwest Biotherapeutics seller in Q3 2015 was Goldman Sachs, an estimated $13.6M sold.
Based on aggregated 13F filings for Q3 2015.